DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/genome-editing-services-world-markets-to-2030-focus-on-crispr---the-most-popular-genome-manipulation-technology-tool-300966100.html

SOURCE Research and Markets

See more here:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - P&T Community

The microscopic advances that are opening big opportunities in cell biology  Nature.com

Read the original here:
The microscopic advances that are opening big opportunities in cell biology - Nature.com

A new study has given more information confirming the status of the unborn child as a being who should not be regarded as anything other than a child: by the second trimester, when the unborn child can detect light in the developing retina, the cells sensing light connect to the perihabenula, which regulates mood, and the amygdala, which is involved with ones emotional state.

Scientists at the University of California, Berkeley have gone beyond known information that already found the retina in the unborn child sensed light in order to help the child become accustomed to 24-hour, day-night rhythms. As Science Daily explains:

In the developing eye, perhaps 3% of ganglion cells the cells in the retina that send messages through the optic nerve into the brain are sensitive to light and, to date, researchers have found about six different subtypes that communicate with various places in the brain. Some talk to the suprachiasmatic nucleus to tune our internal clock to the day-night cycle. Others send signals to the area that makes our pupils constrict in bright light.

Science Daily noted, UC Berkeley graduate student Franklin Caval-Holme combined two-photon calcium imaging, whole-cell electrical recording, pharmacology and anatomical techniques to show that the six types of ipRGCs in the newborn mouse retina link up electrically, via gap junctions, to form a retinal network that the researchers found not only detects light, but responds to the intensity of the light, which can vary nearly a billionfold.

Marla Feller, a UC Berkeley professor of molecular and cell biology, wrote in Current Biology,Given the variety of these ganglion cells and that they project to many different parts of the brain, it makes me wonder whether they play a role in how the retina connects up to the brain. Maybe not for visual circuits, but for non-vision behaviors. Not only the pupillary light reflex and circadian rhythms, but possibly explaining problems like light-induced migraines, or why light therapy works for depression.

Feller added:

We thought they (mouse pups and the human fetus) were blind at this point in development. We thought that the ganglion cells were there in the developing eye, that they are connected to the brain, but that they were not really connected to much of the rest of the retina, at that point. Now, it turns out they are connected to each other, which was a surprising thing In the past, people demonstrated that these light-sensitive cells are important for things like the development of the blood vessels in the retina and light entrainment of circadian rhythms, but those were kind of a light on/light off response, where you need some light or no light. This seems to argue that they are actually trying to code for many different intensities of light, encoding much more information than people had previously thought.

She concluded, In conclusion, we have provided a complete characterization of encoding of ambient light in the neonatal retina and reveal for the first time that gap junction coupling significantly contributes to the heterogeneity of ipRGC light responses. The strength of gap junction coupling is modulated by dopamine, providing a powerful source of modulation of light responses prior to maturation of intraretinal circuits.

View post:
Study Shows Unborn Babies See More Than We Knew - The Daily Wire

Australia's first space research mission to the International Space Station (ISS) will attempt to establish how some of the most aggressive cancer cells behave in a zero-gravity environment.

University of Technology (UTS) researcher Dr Joshua Chou is looking to replicate the promising results of experiments he has carried out on cancer cells in the zero-gravity chamber built by his team in the UTS School of Biomedical Engineering.

Dr Chou organized the first ever Space Biology Symposium at UTS bringing together scientists, investors, government and space enthusiasts to consider advances in space biology and medicine. Topics included research and development of new types of pharmaceuticals, engineered tissues, and emerging medical technologies.

He also announced details of the ISS mission to determine how microgravity can affect some of the hardest cancers to kill: ovarian, breast, nose and lung.

UTS will work with YURI, a German company founded to enable and expand research and commercial applications in microgravity. It will provide the hardware - a bio-module - which will carry the cells into space.

he believes the mission findings could signal to the Australian research community that the era of space biology and medicine is well and truly here.

Cancer involves some body cells dividing uncontrollably and invading tissue, with the cells coming together to form a solid tumor which continues to grow until a point in which the cells are 'signaled' to invade the body.

No one knows exactly when that point is reached.

There must be a means by which cancer cells 'feel' and 'sense' each other in order to form a tumour. We know the only way cancer cells sense their surroundings is through mechanical forces. And those forces only exist when there's gravity."

Dr. Joshua Chou, UTS researcher

In tests in a microgravity environment at UTS, 80 to 90 per cent of the cells in the cancer types were disabled - they either die or float off because they can no longer hold on.

"We're ready to verify if the cells do the same thing in space. My hope is to confirm what we found in the lab and be able to identify new targets and introduce a drug that 'tricks' the cancer cell into thinking it's in space when it's actually still on Earth," he said.

"My vision is that this drug would work alongside existing treatments to improve treatment timespan and efficiency.

"It would not be a magic bullet, but it could give current treatments like chemotherapy a big enough boost to kill the disease."

Dr Chou's previous experience of how the space environment impacts understanding of cell biology and disease progression occurred in research he did at Harvard that created the osteoporotic drug EVENITY. It was developed from research conducted at the ISS, and has been on the market and helping patients for six months.

Read the original post:
Novel out-of-this-world approach to cancer research - News-Medical.net

Open any biology textbook and it becomes instantly clear that this area of study is incredibly complex. From the atomic-level structure of DNA to the relationships between prey and predator populations, biology encompasses an incredibly broad spectrum of molecules, organisms, and systems, all of which scientists are trying to understand in detail.

Yoichiro Moris career is focused on developing mathematical solutions to help address unanswered questions in biology and, in turn, to invigorate mathematics by introducing new questions inspired by biological problems. His research demonstrates how a fundamental mathematical understanding can provide new insights into complex systems and lead to new theoretical developments. Now, as the Calabi-Simons Visiting Professorof Mathematics and Biology, he aims to foster connections between researchers at Penn.

Moris latest research, published in the Proceedings of the National Academy of Sciences, stems from his interest in cell movement. Biologists have studied how cells rearrange their cytoskeleton, internal filaments that give cells structure, and use mechanical forces to move themselves forward. But theres a second force always acting on cells whose role in movement is less understood: osmosis. Osmotic and ionic regulation is a key component of cell biology, but biologists have yet to figure out if it could also play a role in how cells move.

Through a combination of experiments, conducted by collaborators at Johns Hopkins University, and mathematical models, the researchers found that its more advantageous for cells to use their osmosis-powered engines to move when they are in environments with high mechanical resistance, or where the space is crowded by cells or particles. They also found that having a cell membrane thats permeable to water also helped cells move more easily.

This paper is also one of the few studies that could directly compare osmotic engines with cell movement powered by the cytoskeleton, thanks in part to Moris previous work on how cells control their size. Mori was able to apply the thermodynamic framework to this problem, a technique that could be extended to other areas of biology in the future.

Despite his success in using math to help solve biological problems, Mori tries to stay humble. There are a lot of interesting biological questions, but many questions are not inherently mathematical, he says. Part of the challenge is that many systems in biology are quite complicated, especially compared to other natural sciences, like physics, where systems can be modeled more easily. Biology data are also more variable, and there is more uncertainty about how systems actually work.

Science has different phases, Mori explains. At the beginning you have to name things; the first thing is to list everything, and its only then that you can start to understand relationships. Most of biology up to the end of the 20th century was spent on naming things, but with molecular biology we can now start talking about relationships. Now, mathematics can start to play an important role.

Moris own unique academic path has also helped him see firsthand the role of math in biology. While attending medical school at the University of Tokyo, he realized that his passion for math and physics was stronger than for clinical medicine or benchtop research. After finishing his board exams, he made the seemingly unorthodox decision to join a Ph.D. program in mathematics at New York University. I have a lot of respect for experimentalists, in particular because I failed so miserably, says Mori. I found that scribbling equations on paper is the only thing I can actually do, and what I do is comparatively quite easy.

As the Calabi-Simons Visiting Professor, and co-director of the Center for Mathematical Biology, Mori aims to promote this area of research at Penn by bringing together faculty, graduate students, and researchers working at the interface of fundamental mathematics and other fields in the natural sciences like biology and medicine.

Theres so much exciting science going on in every corner of Penn, and I think there can be some really interesting collaborations and synergies, says Mori, adding that Penns strong history in soft condensed matter physics and the research portfolio of the medical school will also be instrumental in his own work on mathematical physiology and biophysics.

Mori also emphasizes Penns collaborative spirit as essential for future progress in this field. What I found through the years is that if you want to do really interesting things, you dont just sit in your office and think, you have to go talk to people. Getting ideas from other people, sharing your ideas with other people, and working with people are essential.

This research was supported by National Science Foundation Grant DMS-1620316.

Yoichiro Mori is the Calabi-Simons Visiting Professor ofMathematics and Biology with appointments in the Department of Mathematics and the Department of Biology in the School of Arts and Sciences at the University of Pennsylvania.

See the original post here:
Where math meets biology - Penn: Office of University Communications

Different patterns formed by the teams minimal biochemical interaction networks. The modular replacements for MinE create this diverse set of patterns when co-reconstituted with MinD on membranes. Credit: Glock et al. CC BY 4.0

Probing the functional segments, or motifs, of proteins has helped scientists identify the minimal ingredients needed for them to form biological patterns.

Writing in the journal eLife, the researchers describe how they dissected the biological phenomenon of protein pattern formation into its main functional modules, and then rebuilt the process from the ground up in a completely new way.

Proteins self-organize to form patterns in living cells, which are essential for key functions such as cell division, communication, and movement. A striking example is the MinDE system of the bacterium Escherichia coli (E. coli). This system produces oscillations of two protein types, MinD and MinE, between two poles of the rod-shaped bacteria, positioning the machinery for cell division to midcell. It can be reconstituted in the laboratory, allowing scientists to control and manipulate the functional elements needed for pattern formation via protein mutations.

Because of its simplicity, the MinDE system has been invaluable in understanding the mechanisms of protein-based pattern formation, says Philipp Glock, a Ph.D. student at the Max Planck Institute of Biochemistry in Munich, Germany, and co-lead author alongside Fridtjof Brauns and Jacob Halatek, both from the Ludwig Maximilians University of Munich. A key question that remains is whether this structural and functional complexity can be reduced further to reveal a set of minimal ingredients for pattern formation.

To answer this, Glock and his colleagues created a minimalistic version of MinE, which plays an antagonistic role in the two-protein MinDE system, by dissecting the protein in a set of core functional motifs, guided by theoretical modeling. One motif, the short helical sequence of amino acids which MinE uses to interact with MinD, is not enough to produce patterns on its own. But adding other functional motifs of MinE one at a time enabled the scientists to fully design new minimal pattern-forming protein mutants.

The team found that at least one other functional motif is required to form patterns. This can either be a motif for membrane binding or a dimerizing motif, which binds to other molecules of the same kind. Neither of these motifs needs to be from native MinE, but can be replaced and potentially simplified further.

Mathematical modeling then allowed the authors to explain why these features are required and how they enable patterns to form. Moreover, they predicted how these patterns adapt to the cell shape in E. coli. The team says that testing these predictions is an exciting goal for future experiments.

Our work provides a starting point for a modular and tunable experimental platform to design protein-based pattern formation from the bottom-up, says Petra Schwille, PhD, Director of the Department of Cellular and Molecular Biophysics at the Max Planck Institute of Biochemistry, and co-senior author alongside theoretical physicist Erwin Frey, from the Ludwig Maximilians University of Munich. She adds that while the patterns created by the new system are less regular than those formed by the native MinDE system, they are still sufficient for reproducing and studying basic biological processes.

The model can now be used to study which functional features, regardless of a particular protein system, need to be combined to allow for self-organization and pattern formation in biology. Our modular approach may also provide the necessary data for computer modeling of pattern formation in other types of bacteria, as well as more complex organisms, Schwille concludes.

Reference: Design of biochemical pattern forming systems from minimal motifs by Philipp Glock, Fridtjof Brauns, Jacob Halatek, Erwin Frey and Petra Schwille, 26 November 2019, eLife.DOI: 10.7554/eLife.48646

Follow this link:
Aiming to to Form Biological Patterns, Scientists Dissect and Redesign Protein-Based Pattern Formation - SciTechDaily

Global Live Cell Imaging Industry Analysis of the value chain helps to analyze major raw materials, major equipment, production processes, customer analysis and major Live Cell Imaging Market distributors. A comprehensive analysis of the statistics, market share, performance of the company, historical analysis Till 2018, volume, revenue, growth rate of YOY and CAGR forecast for 2027 is included in the report. Research Report also provides explicit information in recent years on mergers, acquisitions, joint ventures and other important market activities. Research Analysis report also provides Porter analysis, PESTEL analysis and market attractiveness to better understand the macro-and micro-level market scenario. Live Cell Imaging report also includes a detailed description, a competitive scenario, a wide range of market leaders and business strategies adopted by competitors with their analysis of SWOT.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPHE100001215/

MARKET INTRODUCTION

Live cell imaging is the technique to study live cells with the help of images obtained from imaging systems such as high content screening systems and microscopes. This method is used by the scientists to obtain a better view of the cells biological function by studying the cellular dynamics. In recent years, live cell imaging technology has been widely accepted by various researchers to obtain a better knowledge regarding cell biology. Live cell imaging plays a crucial role in research fields such as neurology, immunology, microbiology and, genetics among others.

MARKET DYNAMICS

Rise in the number of cancer cases along with increase in the number of government funds for R&D activities are expected to be the driving factor in the market in the future years. Use of live cell imaging in the field of personalized medicine is expected to provide growth opportunities in the live cell imaging market during the forecast period.

The report also includes the profiles of key live cell imaging market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Key Competitors In Market are

TOC pointsof Market Report:

Market size & shares

Market trends and dynamics

Market Drivers and Opportunities

Competitive landscape

Supply and demand

Technological inventions in industry

Marketing Channel Development Trend

Market Positioning

Pricing Strategy

Brand Strategy

Target Client

MARKET SCOPE

The Global Live Cell Imaging Market Analysis to 2027 is a specialized and in-depth study with a special focus on the global medical device market trend analysis. The report aims to provide an overview of live cell imaging market with detailed market segmentation by product, technology, application, end users and geography. The global live cell imaging market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading live cell imaging market players and offers key trends and opportunities in the market.

Market segmentation:

Live Cell Imaging Market to 2027 Global Analysis and Forecasts By Product (Equipment, Kits and Reagents, Software, Consumables); Technology (Fluorescence Recovery After Photobleaching, Fluorescence Resonance Energy Transfer, High-content Analysis, Fluorescence In Situ Hybridization, Others); Application (Drug Discovery, Cell Biology, Developmental Biology,, Stem Cells, Others); End User (Pharmaceutical & Biotechnology Companies, Hospitals, Diagnostic Laboratories, Others) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

The target audience for the report on the market

Manufactures

Market analysts

Senior executives

Business development managers

Technologists

R&D staff

Distributors

Investors

Governments

Equity research firms

Consultants

Click to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPHE100001215/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:sales@theinsightpartners.com

Visit link:
Live Cell Imaging Market 2019 Research Report Overview by Top Key Players, Opportunities, Key Drivers, Application and Regional Outlook To 2027 -...

The body is a complex station that is in continuous operation morning, noon, and night. Whatever the hour, our bodies are working hard to make and maintain the various substances needed for us to operate efficiently.

Anytime a substance enters a cell it gets engulfed by some of the cells outer membrane and forms a sac as the result. This sac then becomes a carrier of the substance inside the cell. After this, the cell then merges with an organelle called an endosome.

Endosomes are often referred to as a kind of sorting station. From here the substance either gets recycled and churned back into the cell membrane or it gets thrown forward to the lysosome where it is broken down ready for degradation.

The general consensus is that these endosomes are maintained by a process which allows vesicles moving from the cell membrane to keep fusing into them. However, a recent study published in Communications Biology, suggests these vesicles are far more important than that and play a crucial role in both the formation and maintenance of endosomes.

We used our research to show that endocytic vesicle internalization is not essential, but that vesicle transport from the trans-Golgi network is crucial, states the team from the Tokyo University of Science, who is responsible for the research.

The results of the study were obtained from a series of experiments which introduced either mutations or two drugs, called Brefeldin A and Monensin, into the yeast cell. At first, mutant yeast strains were used. They chose to use these strains as they contain mutations responsible for causing defects during the endocytosis process which in turn, hamper the ingestion of substances at the cell membrane.

When looking at the mutated cells, what they discovered was the protein called Rab5, which is responsible for mediating the formation of endosomes, carried on as normal, initiating and leading normal endosome formation.

The next part of the experiment involved introducing the two drugs into the yeast cell in which to try and stop the transportation of certain vesicles. In doing this they noted that endosome formation was hampered with smaller amounts of Rab5 localized on the endosomes.

After carrying out further experiments, the leader of the study, Prof Jiro Toshima, along with his group, saw that some proteins which are already present in the Golgi or are recruited there, are those responsible for activating Rab5 and the formation of endosomes.

Gathering all the information obtained from these experiments, the team concluded that endocytosis is not required for the formation of endosomes, but the movement from the Golgi is. Our results provide a different view of endosome formation and identify the TGN as a critical location for optimal maintenance and functioning of endosomes, says Toshima. And it is this kind of knowledge that could help in the development of better treatments for a wide range of diseases.

comments

More:
Understanding the Origin of the Cell Organelle and how it is Maintained - TrendinTech

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it has received two Life Science Industry Awards (LSIA) for Most Innovative New Products in 2019 fromBioInformatics Inc. Since 2002, the LSIA have recognized manufacturers of the tools of science that help advance biological research and drug discovery.

It is a great honor for our xCELLigence RTCA eSight, the latest addition to Agilents cell analysis portfolio, to receive one of the Most Innovative New Product in 2019 Award - Cell Biology from Bioinformatics

The Agilent products were theMagnis NGS Prep System, which received a Silver Award in the genomics category, and thexCELLigence RTCA eSight, which received a Bronze Award in the cell analysis category. Agilent was the only life sciences company nominated twice.

Id like to congratulate Agilent for winning not one, but two, Life Science Industry Awards in the categories of cell biology and genomics," said Craig Overpeck, CEO of BioInformatics Inc. xCELLigence RTCA eSight and the Magnis NGS Prep System are examples of Agilents innovative thinking and commitment to driving life science research forward.

The fully automated Magnis NGS Prep System includes reagents and protocols that make it easy to assay multiple genes and complex genetic aberrations from genomic DNA, including degraded samples such as formalin-fixed paraffin-embedded (FFPE).

With complex NGS library preparation, customers often struggle with retaining skilled lab personnel who can routinely produce high-quality results, said Kevin Corcoran, Agilent VP, and general manager for biomolecular analysis. The Magnis was designed as a turn-key automation solution to enable any lab to adopt NGS. Magnis has innovated library prep processing, ensuring optimized, reproducible results that work seamlessly with Agilents SureSelect platform.

The xCELLigence RTCA eSight provides label-free, real-time biosensor measurements, as well as kinetic imaging of the same live cell populations, independently, or simultaneously. It enables scientists to obtain unprecedented information and deep insight into cell health and their responses to a variety of chemical or biological manipulations across a wide spectrum of basic research and therapeutics fields, including cell biology, immunology, immuno-oncology, and immunotherapy.

"It is a great honor for our xCELLigence RTCA eSight, the latest addition to Agilents cell analysis portfolio, to receive one of the Most Innovative New Product in 2019 Award - Cell Biology from Bioinformatics," said Xiaobo Wang, Ph.D., who joined Agilent from ACEA, as general manager of the Flow Cytometry and Real-Time Cell Analysis Business. "The launch of xCELLigence RTCA eSight, with its highly multiplexing capabilities including real-time electronic biosensor measurements and live cell imaging with up to four independent, bright field and fluorescent channels, represents the frontier in live cell analysis. Now researchers can observe cell health and behavior in the greatest mechanistic details to analyze and more fully understand complex cellular environments and interactions through the entire course of the cell-based assay.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20thyear as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available atwww.agilent.com. To receive the latest Agilent news, subscribe to the AgilentNewsroom. Follow Agilent onLinkedIn,Twitter, andFacebook.

Naomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com

Read more:
Agilent Receives Multiple Life Science Industry Awards for Innovation - BioSpace

The buildup of scar tissue makes recovery from torn rotator cuffs, jumpers knee, and other tendon injuries a painful, challenging process, often leading to secondary tendon ruptures. New research led by Carnegies Chen-Ming Fan and published in Nature Cell Biology reveals the existence of tendon stem cells that could potentially be harnessed to improve tendon healing and even to avoid surgery.

Tendons are connective tissue that tether our muscles to our bones, Fan explained. They improve our stability and facilitate the transfer of force that allows us to move. But they are also particularly susceptible to injury and damage.

Unfortunately, once tendons are injured, they rarely fully recover, which can result in limited mobility and require long-term pain management or even surgery. The culprit is fibrous scars, which disrupt the tissue structure of the tendon.

Working with Carnegies Tyler Harvey and Sara Flamenco, Fan revealed all of the cell types present in the Patellar tendon, found below the kneecap, including previously undefined tendon stem cells.

Because tendon injuries rarely heal completely, it was thought that tendon stem cells might not exist, said lead author Harvey. Many searched for them to no avail, but our work defined them for the first time.

Stem cells are blank cells associated with nearly every type of tissue, which have not fully differentiated into a specific functionality. They can also self-renew, creating a pool from which newly differentiated cell types can form to support a specific tissues function. For example, muscle stem cells can differentiate into muscle cells. But until now, stem cells for the tendon were unknown.

Surprisingly, the teams research showed that both fibrous scar tissue cells and tendon stem cells originate in the same space the protective cells that surround a tendon. Whats more, these tendon stem cells are part of a competitive system with precursors of fibrous scars, which explains why tendon healing is such a challenge.

The team demonstrated that both tendon stem cells and scar tissue precursor cells are stimulated into action by a protein called platelet-derived growth factor-A. When tendon stem cells are altered so that they dont respond to this growth factor, then only scar tissue and no new tendon cells form after an injury.

Tendon stem cells exist, but they must outcompete the scar tissue precursors in order to prevent the formation of difficult, fibrous scars, Fan explained. Finding a therapeutic way to block the scar-forming cells and enhance the tendon stem cells could be a game-changer when it comes to treating tendon injuries.

This work was supported by the U.S. National Institutes of Health.

Source:

Carnegie Institution for Science. .

Visit link:
Research: Discovery of tendon stem cells could be a game-changer when it comes to treating tendon injuries, avoiding surgery - Tdnews